²é¿´: 4530  |  »Ø¸´: 69
¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û60´Î£¬×÷Õßzhuimengren639Ôö¼Ó½ð±Ò 56.5 ¸ö
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

[×ÊÔ´] ·ÖÏí£ºµÂ¹úº£µÂ±¤´óѧHugo Kubinyi½ÌÊÚµÄÒ©ÎïÉè¼ÆµÄ¿Î¼þ

µÂ¹úUniversity of HeidelbergµÄÖøÃûÒ©Îﻯѧ¼ÒHugo Kubinyi¹ØÓÚÒ©ÎïÉè¼ÆµÄ¿Î¼þ£¬ÏàÐŶԸãÒ©ÎïÉè¼ÆµÄͬѧ»áÓÐÓõġ£

Èç¹û¸Ð¾õµ¥¸öÏÂÔØÌ«Âé·³£¬ÄÇô¿ÉÒÔÓà flashget/ѸÀ×ÅúÁ¿ÏÂÔØ£¬Ï£Íû´ó¼ÒÄܹ»Ï²»¶£¬Ó»Ô¾ÆÀÂÛ£¡

¿´µ½ÓÐÕâô¶à³æÓÑϲ»¶Õâ¸ö¿Î¼þ£¬ÎªÁ˸Ðл´ó¼Ò£¬ÎÒ°ÑÎÒÏÂÔØµÄ´«µ½ÄÉÃ×ÅÌÉϹ©´ó¼ÒÏÂÔØ£¬µØÖ·ÈçÏÂ
http://www.namipan.com/d/Hugo%20 ... c4504bad9361a9db300


ÄÚÈÝ:

Drug Discovery (758 kBlack Eye
http://www.kubinyi.de/dd-01.pdf

Serendipity and Rational Design (374 kBlack Eye
http://www.kubinyi.de/dd-02.pdf

Chemogenomics (1,453 kBlack Eye
http://www.kubinyi.de/dd-03.pdf

Ligand-Receptor Interactions (647 kBlack Eye
http://www.kubinyi.de/dd-04.pdf

Hydrogen Bonds and Biological Activities (359 kBlack Eye
http://www.kubinyi.de/dd-05.pdf

Chemical Similarity and Biological Activities (686 kBlack Eye
http://www.kubinyi.de/dd-06.pdf

Drug Metabolism (501 kBlack Eye
http://www.kubinyi.de/dd-07.pdf

Peptidomimetics and Prodrugs (294 kBlack Eye
http://www.kubinyi.de/dd-08.pdf

Combinatorial Chemistry Technology (147 kBlack Eye
http://www.kubinyi.de/dd-09.pdf

Combinatorial Chemistry in Drug Research (215 kBlack Eye
http://www.kubinyi.de/dd-10.pdf

QSAR Parameters (284 kBlack Eye
http://www.kubinyi.de/dd-11.pdf

QSAR - Hansch and Free Wilson Analyses (153 kBlack Eye
http://www.kubinyi.de/dd-12.pdf

Variable Selection and Model Validation (935 kBlack Eye
http://www.kubinyi.de/dd-13.pdf

Nonlinear QSAR and 3D QSAR (173 kBlack Eye
http://www.kubinyi.de/dd-14.pdf

QSAR Examples (138 kBlack Eye
http://www.kubinyi.de/dd-15.pdf

Structure-Based Ligand Design (782 kBlack Eye
http://www.kubinyi.de/dd-16.pdf

Computer-Aided Ligand Design (850 kBlack Eye
http://www.kubinyi.de/dd-17.pdf

Pharmacophore Analyses (486 kBlack Eye
http://www.kubinyi.de/dd-18.pdf

Virtual Screening (299 kBlack Eye
http://www.kubinyi.de/dd-19.pdf

Combinatorial and Fragment-Based Ligand Design (945 kBlack Eye
http://www.kubinyi.de/dd-20.pdf

Serine Proteases and their Inhibitors (371 kBlack Eye
http://www.kubinyi.de/dd-21.pdf

Thrombin Inhibitor Design (332 kBlack Eye
http://www.kubinyi.de/dd-22.pdf

Problems in Drug Design (1,043 kBlack Eye
http://www.kubinyi.de/dd-23.pdf

In Search for New Leads
http://www.kubinyi.de/paris-07-05.pdf

From Leads to Drugs
http://www.kubinyi.de/wien-06-05.pdf

Validation and Predictivity of QSAR Models
http://www.kubinyi.de/istanbul-2004-lecture.pdf

[ Last edited by zhuimengren639 on 2008-10-25 at 22:39 ]
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

¸öÈËËѼ¯¾«»ª

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

gp0713

Òø³æ (СÓÐÃûÆø)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

very good£¡thanks£¡
3Â¥2008-10-24 21:59:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 70 ¸ö»Ø´ð

xufund

ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

very good
thanks
2Â¥2008-10-24 21:09:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lijianyong

½ð³æ (ÕýʽдÊÖ)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

ºÃµÄºÜ°¡
лл
ÓйØÒ©ÎïÉè¼Æ¶¼»¶Ó­
5Â¥2008-10-25 03:15:15
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

tnt

ľ³æ (ÖøÃûдÊÖ)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

ÐÒ¿àÁË£¬Ð»Ð»£¡£¡
6Â¥2008-10-25 07:02:51
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
2008-10-24 22:03   »Ø¸´  
 
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Çó²ÄÁϵ÷¼Á +8 ¸ô±Ú³ÂÏÈÉú 2026-03-12 8/400 2026-03-18 22:19 by li123456789.
[¿¼ÑÐ] Ò»Ö¾Ô¸Öк£Ñó²ÄÁϹ¤³Ìר˶330·ÖÇóµ÷¼Á +5 С²Ä»¯±¾¿Æ 2026-03-18 5/250 2026-03-18 21:53 by ÎÞи¿É»÷111
[¿¼ÑÐ] 281Çóµ÷¼Á£¨0805£© +6 ÑÌÏ«Ò亣 2026-03-16 15/750 2026-03-18 21:12 by Gaodh_82
[½Ìʦ֮¼Ò] ½¹ÂÇ +8 Ë®±ùÔÂÔÂÒ°Íà 2026-03-13 12/600 2026-03-18 15:27 by ßäÎØß÷ÎØ
[¿¼ÑÐ] 08¹¤¿Æ 320×Ü·Ö Çóµ÷¼Á +5 À滨çóÍí·ç 2026-03-17 5/250 2026-03-18 14:49 by haxia
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤Ò»Ö¾Ô¸Äϲý´óѧ327Çóµ÷¼ÁÍÆ¼ö +8 Ncdx123456 2026-03-13 9/450 2026-03-18 14:40 by haxia
[¿¼ÑÐ] 302Çóµ÷¼Á +10 ºôºôºô¡£¡£¡£¡£ 2026-03-17 10/500 2026-03-18 12:45 by Linda Hu
[¿¼ÑÐ] 288Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÄÏÀí¹¤´óѧ071005 +4 ioodiiij 2026-03-17 4/200 2026-03-18 12:36 by Linda Hu
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á +4 pupcoco 2026-03-17 7/350 2026-03-18 12:14 by djl2006
[¿¼²©] »·¾³ÁìÓòÈ«¹úÖØµãʵÑéÊÒÕÐÊÕ²©Ê¿1-2Ãû +3 QGZDSYS 2026-03-13 5/250 2026-03-18 11:13 by QGZDSYS
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼ÑÐ] 308Çóµ÷¼Á +4 ÊÇLupa°¡ 2026-03-16 4/200 2026-03-17 17:12 by ruiyingmiao
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +5 Ð÷ÐÒÓë×Ó 2026-03-17 5/250 2026-03-17 16:40 by laoshidan
[¿¼ÑÐ] 278Çóµ÷¼Á +3 Yy7400 2026-03-13 3/150 2026-03-17 08:24 by laoshidan
[¿¼ÑÐ] 277²ÄÁÏ¿ÆÑ§Ó빤³Ì080500Çóµ÷¼Á +3 ×ÔÓɼå±ý¹û×Ó 2026-03-16 3/150 2026-03-16 14:10 by ÔËÆøyunqi
[¿¼ÑÐ] ÇóÀÏʦÊÕÁôµ÷¼Á +4 jiang½ª66 2026-03-14 5/250 2026-03-15 20:11 by Winj1e
[¿¼ÑÐ] 330Çóµ÷¼Á +3 ?½´¸øµ÷¼Á¹òÁË 2026-03-13 3/150 2026-03-14 10:13 by JourneyLucky
[¿¼ÑÐ] ¿¼Ñе÷¼Á +4 ·Ò´ï46 2026-03-12 4/200 2026-03-13 16:04 by ruiyingmiao
[¿¼ÑÐ] ¹¤¿Æ²ÄÁÏ085601 279Çóµ÷¼Á +8 À§ÓÚÐdz¿ 2026-03-12 10/500 2026-03-13 15:42 by ms629
[¿¼ÑÐ] 328»¯¹¤×¨Ë¶Çóµ÷¼Á +4 ¡££¬¡££¬¡££¬¡£i 2026-03-12 4/200 2026-03-13 14:44 by JourneyLucky
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û